7754 Stock Overview
Develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AnnJi Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$42.80 |
| 52 Week High | NT$72.40 |
| 52 Week Low | NT$39.05 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7754 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.6% | -1.6% | -4.6% |
| 1Y | n/a | 9.8% | 31.4% |
Return vs Industry: Insufficient data to determine how 7754 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 7754 performed against the TW Market.
Price Volatility
| 7754 volatility | |
|---|---|
| 7754 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 7754 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7754's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Wendy Huang | www.ajpharm.com |
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy, a neurodegenerative disease; AJ202 for androgenetic alopecia; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. Fundamentals Summary
| 7754 fundamental statistics | |
|---|---|
| Market cap | NT$4.00b |
| Earnings (TTM) | -NT$329.22m |
| Revenue (TTM) | NT$143.53m |
27.9x
P/S Ratio-12.2x
P/E RatioIs 7754 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7754 income statement (TTM) | |
|---|---|
| Revenue | NT$143.53m |
| Cost of Revenue | NT$125.09m |
| Gross Profit | NT$18.44m |
| Other Expenses | NT$347.66m |
| Earnings | -NT$329.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.52 |
| Gross Margin | 12.85% |
| Net Profit Margin | -229.37% |
| Debt/Equity Ratio | 0% |
How did 7754 perform over the long term?
See historical performance and comparison